PExA AB (publ) develops and commercializes diagnostic products in various respiratory diseases, such as asthma, tuberculosis, cystic fibrosis, lung cancer, chronic airway inflammation, and chronic obstructive pulmonary diseases. Its research instrument helps lung researchers in the collection of microscopic particles and biomarkers for diseases in the small airways. The company offers PExA 2.0, an instrument for the non-invasive collection of particles in exhaled air. It also provides accessories, which includes substrate surfaces and nozzles, parts, and service kits, as well as support services. The company provides its products for lung research centers within the health services, academia, and pharmaceutical companies. PExA AB (publ) has a research collaboration agreement with Janssen Research & Development, LLC and the University of Gothenburg for the discovery of biomarkers in exhaled air. The company was founded in 2004 and is based in Gothenburg, Sweden.